epidermal growth factor biosimilar

EGF biosimilar is a recombinant protein candidate developed by the Iranian biopharmaceutical company Tekzima through its Noargen platform. It is a biosimilar version of recombinant human epidermal growth factor (rhEGF). The drug acts as an agonist of the epidermal growth factor receptor (EGFR), mimicking the activity of endogenous EGF to stimulate intracellular signaling pathways such as MAPK/ERK and PI3K/Akt. These pathways are critical for promoting cell proliferation, differentiation, and survival, which are essential processes for tissue repair and wound healing. While specific clinical indications were not explicitly detailed in the company's archived pipeline, recombinant EGF is typically utilized in the treatment of chronic wounds, such as diabetic foot ulcers, to accelerate the healing process. The product is currently in the preclinical stage of development.

Other names

EGF biosimilarrecombinant epidermal growth factorepidermal growth factor biosimilar-Tekzima Company-EGFR-biosimilar-recombinant protein